Policy or Poll Approval?
Image courtesy of @BloombergLaw

Policy or Poll Approval?

A Look at the Trump Administration’s Pharmaceutical Pricing Policy Proposals

Drug pricing is a critically important issue to America voters. Since Donald Trump’s 2016 campaign promise to replace Obamacare with his own version of an affordable health care act for America, drug prices have continued to soar. 

American voters are angry and their feelings must be palpable as Trump continues to seek public approval by pushing policy and making drug-prices a political-platform in the upcoming 2020 election.

Drug prices are one of the most visible parts of the U.S. health-care system. So it’s top-of-mind.

Trump is fixated on polls and American voters are fixated on drug prices. This threat of public disapproval is prompting Trump into a reactionary pattern as clearly evinced by the timeline of his proposals over the past year and a half.

When Drug Prices Jump, So Does Trump — If He Sees It on the News via @BloombergLaw

In July of 2018 drug list-prices increased by 8.4%, and within 4 days Trump had called an Oval Office meeting with Health Secretary Alex Azar to discuss the matter. A few months later in October, the Trump administration fast tracked the release of the proposed 'International Pricing Index model', which has been criticized by the Pharmaceutical Research and Manufacturers of America as a counterintuitive measure that could hinder Americans’ access to innovative drug technologies. 

Prices soared again by 6.7% in January 2019. Trump called an Oval Office meeting, and by the end of the month the drug rebate rule was introduced and touted as a plan for transparency within the industry. Yet again, the proposal was met with criticism, and was withdrawn in July 2019. 

Most recently, this past summer drug prices skyrocketed by 14.4%, and with the price increase, the emergence of a clear pattern: within a few days of news of the increase, Trump held another meeting with high-level staffers, and implementation of a favoured nation clause — something the U.S. typically employs in dealings with countries, not companies — was discussed.

This unfolding pattern of a spike in prices followed by a swift reaction indicates that public approval — not industry practices — are what drive Trump’s decisions.

When drug prices jump, so does Trump. 

Anytime Trump sees a story about ‘pharma’ companies raising their prices, he’s going to react. This ‘knee-jerk’ reaction should pose a cautionary-tale to the drug industry. If drug prices continue to climb at the rate they have over the past two years, the concomitant public outcry will continue to spur Trump to action — especially in view of a forthcoming election. And, something is bound to stick. This repeated roll out of proposals at the rate they’ve been released are bound to eventually take hold in the shape of an official policy, most likely by way of increased regulations and restrictions on pricing in the U.S. 

Self-regulation, restraint and a more responsible approach to pricing is needed in the U.S. drug industry, or else repercussions by-way-of Donald Trump may be the consequence.

Richard Phillips

Principal & Managing Director at Goffin Consultancy Ltd

5 年

cause or effect?

回复

要查看或添加评论,请登录

Tuhin A. Rahman的更多文章

  • Drug Pricing in the 2020 U.S. Presidential Election

    Drug Pricing in the 2020 U.S. Presidential Election

    What impact will the U.S.

    4 条评论
  • President Trump, Drug Prices, & Executive Orders – Here's What You Need to Know

    President Trump, Drug Prices, & Executive Orders – Here's What You Need to Know

    With no new laws on the horizon to curb biopharmaceutical pricing, U.S.

  • The Public Option

    The Public Option

    A Look at Pharma Industry Alternatives Recently the Democracy Collaborative, a United States based nonprofit…

    1 条评论
  • The French Solution - How Drugs are Valued in France.

    The French Solution - How Drugs are Valued in France.

    France has a well-established health-technology-assessment system, dating back to the 1980s. The country is also a key…

    5 条评论
  • Industrial Hits

    Industrial Hits

    A Look at the Products that have made the Pharmaceutical industry a House-Hold Name. There are blockbusters.

  • Baseless and Bottomless

    Baseless and Bottomless

    A Look at ICER’s Unsupported Drug Price Increase Report The Institute for Clinical and Economic Review (ICER), a…

  • The Issue with Interchangeable Insulin

    The Issue with Interchangeable Insulin

    Today, three companies control virtually the entire global market for insulin. The creation of insulin for human use to…

  • The Illusion of Innovation: Drug Development and Advances in Europe

    The Illusion of Innovation: Drug Development and Advances in Europe

    More than half of new drugs entering the German healthcare system have failed to demonstrate any added benefit. A…

  • The Weight of the World

    The Weight of the World

    Predictions and Solutions for a Global Obesity Epidemic In October 2019, the World Obesity Federation published a…

  • Pills and The Public Opinion

    Pills and The Public Opinion

    A New Low for the Pharmaceutical Industry's Image Pharmaceuticals companies are astoundingly unpopular in the US…

社区洞察

其他会员也浏览了